Yiling Pharmaceutical announced that Yiling Pharmaceutical and its subsidiary Beijing Yiling Pharmaceutical had received the approval document of drug supplement application concerning the application for new indications of Lianhua Qingwen capsules and Lianhua Qingwen granules issued by State Drug Administration.
The Feinstein Institutes for Medical Research, the research arm of Northwell Health, announced today it has formally joined a national network formed by Mayo Clinic to collect convalescent plasma from patients previously identified with COVID-19, but no longer symptomatic.
BlueWillow Biologics®, a clinical-stage biopharmaceutical company, today announced the company will advance the manufacturing and commercialization of NanoBio® Protect, a nasal antiseptic solution that can be used to help reduce germs that could cause infections.
Biohaven Pharmaceutical Holding Company Ltd. announced a successful end of Phase 2 clinical and nonclinical interaction with the U.S. Food and Drug Administration (FDA) for intranasal vazegepant for the acute treatment of migraine.
Univar Solutions Inc. a global chemical and ingredient distributor and provider of value-added services, today announced the extension of its Pharmaceutical Ingredients as a Dedicated Industry Vertical into Europe, Middle East and Africa.
BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the completion of a 50-subject human clinical trial with the BD Libertas™ Wearable Injector.
TurtleTree Labs, the Singapore-based company working with biotechnology to create the full nutritional content of milk, announced that it has completed its pre-seed funding round.
My Green Lab is pleased to announce a collaboration with AstraZeneca to implement a global-scale green labs program across their research sites as part of their commitment to sustainability, including protecting the environment.
Synthego, the genome engineering company, today announced it has adopted Good Manufacturing Practice (GMP) standards to provide academic and industry partners with high-quality reagents for use in clinical research and development (R&D).
CollPlant, a regenerative medicine company, today announced it is now part of a new public-private ManufacturingUSA initiative, the Advanced Regenerative Manufacturing Institute (ARMI).